Particularităţi clinice şi terapeutice în dermatofibrosarcomul protuberans – studiu de caz
Dermatofibrosarcoma protuberans (DFSP) is a rare form of skin cancer characterized by local aggressiveness, typically affecting individuals in the young to middle-aged adult range. The authors of this article aimed to present the clinical picture, as well as the therapeutic approach to a patient und...
Saved in:
Published in | Oncolog-hematolog ro Vol. 1; no. 1; pp. 16 - 21 |
---|---|
Main Authors | , , , , , |
Format | Magazine Article |
Language | English |
Published |
27.03.2024
|
Online Access | Get full text |
Cover
Loading…
Summary: | Dermatofibrosarcoma protuberans (DFSP) is a rare form of skin cancer characterized by local aggressiveness, typically affecting individuals in the young to middle-aged adult range. The authors of this article aimed to present the clinical picture, as well as the therapeutic approach to a patient undergoing oncological surveillance with DFSP, analyzing the therapeutic response rate based on data published in specialized journals. A 72-year-old man was admitted to the radiation oncology department, having
a 75/58 mm tumoral mass on the right posterior cervical region. The patient underwent two radical tumor excision surgeries and interval skin grafting, leading to a negative prognosis for the patient, as the tumor reappeared aggressively in a short period, four months, more exactly. The study highlighted the importance of surgical intervention, such as wide local excision, in preventing recurrence and the major role of initiating timely adjuvant treatment, including radiotherapy. The previously performed studies
suggest that radiotherapy can be beneficial following resection with negative margins, and it can serve as primary therapy for patients with inoperable or incompletely excised DFSP. In this case, the only therapeutic response was stopping the progression of the tumor growth and macroscopic changes of the tumor surface with areas of necrosis. This study also discusses the use of imatinib as the only left therapeutic option, due to the lack of radiotherapy response. |
---|---|
ISSN: | 2066-8716 |
DOI: | 10.26416/OnHe.66.1.2024.9382 |